Welcome to our dedicated page for NetraMark Holdings news (Ticker: AINMF), a resource for investors and traders seeking the latest updates and insights on NetraMark Holdings stock.
NetraMark Holdings Inc. reports developments tied to artificial intelligence for clinical trial optimization and precision medicine in the pharmaceutical industry. Its recurring updates center on the NetraAI platform, which is designed to analyze complex clinical datasets, identify model-derived patient subgroups, and support patient stratification, enrichment strategies, and trial-design decisions.
Company news commonly covers pharmaceutical and research collaborations, contracts to analyze clinical trial data, peer-reviewed work, conference presentations, and clinical leadership additions. Reported therapeutic areas include central nervous system disorders, depression, Alzheimer’s disease, oncology, and regulated botanical wellness, with emphasis on explainable analytics, biomarker-guided insights, and responder or placebo-sensitive patient populations.
NetraMark (OTCQB: AINMF) has engaged AM Public Relations, a healthcare-focused communications agency, to support its strategic communications and market awareness. The collaboration is intended to help communicate NetraMark’s clinical development initiatives, its proprietary NetraAI platform, and broader scientific and commercial progress.
According to NetraMark, AM PR will assist in reaching key audiences such as investors, potential partners, industry stakeholders, and the healthcare community by translating complex clinical trial and AI technology concepts into clear narratives that highlight NetraAI’s role in generating insights from clinical trial data and in explainable AI for drug development.
NetraMark (OTCQB: AINMF) signed a new contract to analyze a phase 2 neurodegeneration clinical trial dataset through its contract research organization (CRO) partner, marking its first engagement routed via a CRO.
The project uses the proprietary NetraAI platform to identify explainable Model-Derived Subgroups and treatment-response patterns in central nervous system (CNS) disorders, aiming to support patient stratification, trial design, and future drug-development decisions.
NetraMark (OTCQB: AINMF) signed a new NetraAI clinical trial analysis agreement with a biopharmaceutical company developing a late-stage central nervous system therapy. This is NetraMark’s ninth commercial contract since October 2025, highlighting growing use of its AI platform in late-stage clinical development.
NetraAI will analyze patient-level data from a completed mid-to-late-stage trial, generating insights on dose response, efficacy, safety, tolerability, cognition, functional outcomes, discontinuation patterns, and patient stratification to support the client’s late-stage program decisions.
NetraMark (OTCQB: AINMF) will deliver a corporate presentation at the virtual Sidoti Small Cap Conference on June 18, 2026, at 9:15 a.m. ET. Senior management will discuss commercial, clinical, and regulatory progress for NetraAI, its proprietary AI platform for pharmaceutical clinical trials.
NetraMark will also hold one-on-one virtual meetings on June 17–18, 2026.
NetraMark (OTCQB: AINMF) will participate in the American Society of Clinical Psychopharmacology Annual Meeting in Miami from May 26–29, 2026. Founder Dr. Joseph Geraci joins a plenary on AI in psychiatry, and the company presents two posters on explainable AI–driven precision psychiatry using its NetraAI platform.
NetraMark (OTCQB: AINMF) reported a second quarter 2026 update, emphasizing commercial, scientific, regulatory and capital markets progress for its NetraAI clinical trial analytics platform.
Key items include a Cdn$3.5M private placement, TSX uplisting, new pharma contracts, growing proposals, and a Cdn$2.96M revenue backlog.
NetraMark (OTCQB: AINMF) appointed Dr. Panteli Theocharous as Fractional Chief Medical Officer on May 4, 2026, to support global deployment of the NetraAI platform. Dr. Theocharous will continue his roles at Worldwide Clinical Trials and will advise on clinical strategy, trial design, patient stratification, and regulatory translation. Outgoing CMO Dr. Larry Alphs will remain as an advisor to ensure continuity.
NetraMark (OTCQB: AINMF; TSX: AIAI) will open trading on the Toronto Stock Exchange on May 5, 2026 at the market open ceremony. Senior management will perform the market open at 9:30 AM ET, and the event will be livestreamed.
NetraMark develops the NetraAI platform for clinical trial optimization and patient stratification, and the market open highlights ongoing investor engagement and recent collaborations in oncology and other therapeutic areas.
NetraMark (OTCQB: AINMF) highlights its NetraAI platform as a purpose-built analytics solution to support psychedelic and CNS clinical trials amid recent U.S. executive action. The company cites peer‑reviewed validation in npj Digital Medicine and Frontiers in Pharmacology, ongoing psychedelic trial programs, and an emphasis on explainable, regulator‑ready subgroup identification.
NetraMark stresses that policy momentum does not lower regulatory evidence standards and positions NetraAI to improve patient stratification, signal detection, and trial design for small, heterogeneous datasets.
NetraMark (OTCQB: AINMF) commented on the U.S. Executive Order of April 18, 2026 to accelerate treatments for serious mental illness, including investigational psychedelic programs. NetraMark urged rigorous, regulatory‑grade trial design and highlighted its NetraAI platform for explainable subgroup analytics to improve signal detection in CNS trials.